Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shandong Boan Biotechnology Co., Ltd.
山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6955)

VOLUNTARY ANNOUNCEMENT

THE COMPANY ENTERS INTO LICENSING AGREEMENT FOR DENOSUMAB INJECTION 60 MG IN JAPAN

The board of directors (the "**Board**") of Shandong Boan Biotechnology Co., Ltd. (the "**Company**") announces that the Company has entered into a licensing agreement with a partner for BA6101, a 60 mg denosumab injection, in Japan. Under the agreement, the partner will receive exclusive commercialization rights to BA6101 in Japan, including promotion, sales and regulatory submissions, and will be fully responsible for its market access in the Japanese market. The Company will receive an upfront payment, milestone payments and royalties on sales.

Denosumab is a RANK ligand (RANKL) inhibitor. BA6101 is a biosimilar to the reference denosumab product Prolia® (marketed as Pralia® in Japan). Pralia® has been approved in Japan for the treatment of osteoporosis and the inhibition of the progression of bone erosion associated with rheumatoid arthritis.

In Japan, there are approximately 15.9 million osteoporosis patients aged 40 and above and approximately 825,000 rheumatoid arthritis patients, reflecting a long-standing need for fracture prevention and management of bone erosion. Publicly available data show that sales of Pralia® in Japan amounted to JPY45.8 billion in FY2025, representing a year-on-year increase of 8.3%. In addition, the Japanese government aims to achieve a biosimilar replacement rate of 80% for at least 60% of existing Active Pharmaceutical Ingredients (APIs) by the end of FY2029. Together, these clinical needs and supportive policies create favorable conditions for the adoption of high-quality, affordable biosimilars in Japan.

The Company will work closely with its partner, integrating resources and leveraging complementary strengths to jointly improve patients' access to BA6101 in Japan. This collaboration also marks another milestone in the Company's continued efforts to bring its independently developed products to overseas markets.

BA6101 was independently developed by the Company under its global research and development strategy, in strict compliance with the biosimilar guidelines of the U.S., the EU, the U.K., Japan and China. A stepwise program of comparative quality, nonclinical, human pharmacokinetic and clinical efficacy studies demonstrated that BA6101 is highly similar to the reference product, with no clinically meaningful differences with the reference product in safety, purity or potency.

In 2022, BA6101 was approved for marketing in China as the country's first domestically developed denosumab. The Company is also advancing the registration of BA6101 in overseas markets. BA6101 has been approved for marketing in Bolivia, and its Marketing Authorization Application (MAA) in the U.K. and Biologics License Application (BLA) in the U.S. are currently under review, with approvals expected successively within the next year. The Company will further expand the drug into additional countries and regions. It has put into place a network of partners to commercialize the drug in countries and regions, including the U.S., Southeast Asia and Latin America.

By Order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua
Chairlady, Chief Executive Officer and Executive Director

Yantai, the People's Republic of China, 30 October 2026

As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.